Because of the favorable effects of combination therapy observed above, we further analyzed the potential action of NZ001 (Fig. 4a, b and Additional file 1: Table S6), a novel ATP-competitive multi-targeted kinase inhibitor that simultaneously blocks MET and VEGFR2, in HCC. Here, MET is linked to hepatocellular carcinoma.